(Adnkronos) - In questo numero: Vaccini fondamentali per la salute dei bambini e per il benessere della comunità Johnson & Johnson e Fondazione mondo digitale Ets lanciano 5a edizione di ‘Fattore J’ L’efficacia di mepolizumab nella granulomatosi eosinofilica con poliangite (Egpa) E ancora Virus respiratorio sinciziale: dai fattori di rischio al vaccino anti-Rsv anche per gli adulti La Fism compie 40 anni e guarda al rilancio del Sistema sanitario nazionale Con ribociclib -28.5% sul rischio relativo di recidiva in donne con tumore della mammella ormonosensibile precoce. A seguire la 2° puntata della Serie “Libertà visiva. Un nuovo modo di vedere il mondo” dal titolo: Lenti intraoculari ICL restituiscono libertà visiva senza limiti a chi soffre di miopia e difetti visivi
Category
🗞
NewsTranscript
00:00In this issue, fundamental vaccines for the health of children and for the well-being of the community.
00:17Johnson & Johnson and the ETS Digital World Foundation launch the fifth edition of Fattore J.
00:24The effectiveness of mepolizumab in eosinophilic granulomatosis with napoleangites and GPA.
00:31And again, syncytial respiratory virus, from the risk factors to the anti-RSV vaccine also for adults.
00:38The FISMO is 40 years old and is looking at the relaunch of the national health system.
00:44With ribociclib, minus 28.5% on the relative risk of recidivism in women with precocious hormonal-sensitive mammary tumor.
00:54To follow, the second episode of the series is Visible Freedom, a new way of seeing the world
00:59from the title Intraocular Lenses, ICL, restore unlimited visual freedom to those who suffer from myopia and visual defects.
01:07What is the importance of vaccination for the health of children and for the well-being of the community?
01:18Vaccination of newborns is of crucial importance for public health and the well-being of the community.
01:24The first months of life of newborns, in fact, are a particularly vulnerable period
01:28during which the little ones are exposed to various potentially serious infectious diseases.
01:32A fact underlined in Naples, during the Mission Vaccinale convention sponsored by the Italian Pediatric Federation's Campana section,
01:40which made the point on the current state of vaccinations in the region,
01:43highlighting the importance of vaccination coverage for the health of children.
01:47For us pediatricians, there is no difference between mandatory and recommended vaccinations.
01:52On the mandatory, it is obvious that there is a tighter control,
01:55because obviously they are the ones that then give the child the possibility to access society,
01:59so the school and all the rest.
02:01While, on the other hand, the recommended ones are the ones that, in my opinion, have the most important impact,
02:06because they are serious diseases, not so incidental, but above all they are very complicated,
02:13because they are serious diseases and we must distinguish them, not to call them more as it once was,
02:17in fact, that's how it is, vaccinations, let's say, are recommended and not so-called mandatory and optional reactions.
02:24It is no longer an option, it is simply a protection that we want to be given to the child
02:29and therefore we must respect the recommendations for these vaccinations, which are very important.
02:35In Campania, the data on the coverage show encouraging numbers,
02:39with an increase in the adhesion of families to vaccinations, thanks to the fundamental role of pediatricians.
02:44Today we can say that, as far as mandatory vaccines are concerned,
02:47the coverage is very, very well covered
02:51and now we are notably increasing these recommended vaccinations in this period,
02:56in addition to which we have these last ones, which are really urgent
03:01and which notably improve the vaccination coverage.
03:05I am referring to HPV, meningococcus and also to RSV,
03:09which is going very hard to cover these children who must be vaccinated.
03:16Diseases such as meningitis or pneumonia can have devastating consequences,
03:20but thanks to vaccines, the risk of contracting them is reduced significantly.
03:24Losing this possibility of not vaccinating your own children,
03:27putting them at risk of a disease that still exists
03:30and when it is present, it is not a simple disease,
03:33it is a disease that often leads to fatal success,
03:36we must increase the adhesion to the vaccination field.
03:42It is logical that for meningitis B, which is a particular vaccine,
03:45it must also be defined in the proposition of the vaccine
03:51and in this there is also the participation of the free choice paediatricians,
03:54which is fundamental in my opinion.
03:56With continuous collaboration between health institutions, paediatricians and families,
04:00it is possible to further improve the vaccination coverage in the countryside,
04:04thus guaranteeing effective protection for all children
04:07and contributing to a healthier community.
04:10You have to have faith in science, you have to have faith in your paediatrician
04:15because when there are recommendations,
04:18there are years, decades of studies behind these recommendations,
04:22so you have to trust these properties and then you see them on the field,
04:26we have seen it with papilloma, which is giving excellent results.
04:29Vaccinating a child means preventing a problem.
04:38The role of artificial intelligence in the creation of medicine of the future
04:42is at the center of the fifth edition of Fattore J,
04:44the initiative of Johnson & Johnson and Fondazione Mondo Digitale TS
04:47that aims to raise awareness among young generations
04:50about the value of innovation in the field of health.
04:53As shown by the survey conducted by SVG for Johnson & Johnson,
04:57over 60% of young people of Generation Z
05:00believe that scientific research and medicine
05:02are the sectors that will bring the greatest benefits from artificial intelligence,
05:06towards which they nurture a deep trust,
05:08convinced that this technology will have a positive impact on the health of the future,
05:12making it faster, organized, effective and personalized.
05:16Fattore J is the fifth edition of our social responsibility project.
05:22As Johnson & Johnson, we bring innovation in many ways,
05:27therapeutic innovation in clinical research, in development,
05:31but above all we also want to deal with information.
05:35Information of the youngest,
05:37so with this project we want to try to build a bridge
05:43between the school and the world of health.
05:46It is clear that young people are certainly interested in this concept.
05:52We know, however, that we are surrounded by many new things,
05:55artificial intelligence that permeates our daily reality
05:59and that transforms and will transform the world of health more and more.
06:03Already in its previous editions,
06:05the project involved a large number of students, institutions and associations.
06:09We have already trained 30,000 students,
06:12reached 300,000, in collaboration with 18 patient associations,
06:17more than 180 schools, 5 institutions, research institutes,
06:23such as the National Institute for Tumors in Milan, which hosts us today,
06:27so a great ecosystem on the health of the country.
06:30Five, the elements that link technological innovation to oncology,
06:33as explained by the director of the National Institute for Tumors,
06:36of which scientific collaboration is based, Dr. Jay.
06:39Four are the elements, prevention, screening, assistance, research.
06:45These are all the four elements that have within them innovation,
06:49pharmacological technology and tools.
06:51We add a fifth, artificial intelligence.
06:54I believe that artificial intelligence and these guys on artificial intelligence
06:58will have their say.
07:00I think it could be an additional element to exploit and use.
07:08With an incidence of 0.5 and 4.2 cases per million people
07:13and a prevalence between 10 and 14 cases per million,
07:16eosinophilic granulomatosis with polyangiitis and GPA
07:21is a rare disease that affects blood vessels of small, medium and large sizes,
07:25involving several organs.
07:27It is a subdued disease and for this, for diagnosis,
07:30it can take between 7 and 10 years.
07:32Alarm bell, the excessive increase of eosinophils,
07:36cells of the immune system.
07:38They are usually patients who have asthma for years,
07:42they have chronic rhinosinusitis, often with polyposis,
07:45they are also operated two or three times.
07:48At a certain point, there is a significant increase in eosinophils
07:53and so one of the important things to say is to always check the eosinophils,
08:00a hemochrome with the formula, to see if there are normal or increased.
08:06Because if they increase in a really important way,
08:10like over 5, 10,000, 15,000, they can then infiltrate the organs
08:15and then there becomes the problem.
08:17GPA, already known as Churg-Strauss syndrome,
08:21was dedicated to the EGPA press conference,
08:24treatment opportunities with mepolizumab
08:27and the role of the pneumologist, organized in Milan by GSK,
08:31an appointment in which new therapeutic approaches were also discussed.
08:35The advent of new therapies extremely targeted,
08:38such as mepolizumab, which blocks circulating interleukin-5,
08:43allows us to target in an extremely specific way
08:46the path of type 2 inflammation,
08:48reducing quickly the circulating and tissue eosinophil,
08:52therefore checking all those eosinophilic manifestations
08:56that characterize the relapses that these patients have.
08:59This allows us to significantly reduce the exposure to cortisone
09:04and clearly improve the quality of life of these patients.
09:08The impact of EGPA on the life of patients involves both the physical and psychological level,
09:13it is essential for them to have a perspective of care.
09:16Today patients can live a life as normal as possible,
09:21as far as I can handle the term difficulties,
09:25and certainly they have a therapeutic horizon,
09:28a very different horizon of care compared to a time.
09:3689% of respiratory disease deaths
09:40have been recorded in over 65 years
09:43for a total of 5,800 people,
09:46against a total of 116 up to 4 years of age.
09:49These are the data from an American study on the mortality rate for RSV
09:53between 1999 and 2018,
09:56which underlines how such a virus represents a significant threat
10:00to public health, where adults are perhaps the most at risk.
10:04It was discussed during the press conference of GSK
10:07held in Rome, where it was discussed the threat,
10:10the epidemiology of the impact and the solutions that concern this type of virus.
10:15RSV is a virus that is transmitted by air,
10:18by air from person to person,
10:21and produces effects on the high and low respiratory tracts,
10:25from simple colds to pneumonia, deep bronchitis,
10:32and obviously a respiratory commitment, a respiratory insufficiency
10:37in older people who may have chronic diseases,
10:40other intercurrent diseases, such as morbidity,
10:43it really becomes a serious virus.
10:46RSV can also be said to be a really serious virus.
10:51The approval of the adjuvated vaccine against the RSV of GSK
10:56represents a fundamental turn to protect the vulnerable population
11:00for age or other pathologies,
11:03offering a new tool to defend against this infection.
11:06The characteristics of this vaccine are mainly the fact
11:11that it has been developed specifically for the target population,
11:15and therefore for the adult, elderly population,
11:18with a high level of immunosensitivity.
11:21Consequently, it has been combined with an antigen,
11:24a specific antigen, i.e. the protein F in its conformation and profusion,
11:30to what is an adjuvant system.
11:32The adjuvant system, in particular the AS01E system,
11:36has been designed specifically to increase the immune response
11:42and therefore provide greater protection to this particularly vulnerable population.
11:47According to the scientific evidence of the HTA study,
11:50the vaccine against the syncytial respiratory virus
11:53represents an effective technology for at least three consecutive seasons.
11:57I would like to point out that this is the only technology we have given,
12:01so to speak, complete.
12:03It is an effective and safe vaccine that protects the individual,
12:06protects the community, and is based on the protection of everyone
12:09and on the evidence that we have available,
12:11and we hope that our decision-makers can make the right decisions
12:15in the field of protection of the community.
12:17And therefore the anti-RSV vaccination, let's remember,
12:20is not only a pediatric problem, but a problem for adults at risk and for the elderly.
12:28Strengthening of territorial medicine,
12:31training of medical personnel,
12:33prevention, attention to vulnerable areas,
12:36reforms to relaunch and make the national health system sustainable.
12:40These are the main issues addressed during the fourth stage
12:44of the General States of the Federation of Italian Medical and Scientific Societies,
12:48which celebrates its 40th anniversary this year.
12:51Preventing is better than curing,
12:53so we had at the Ministry of Health in November
12:57a two-day event dedicated to 360 degrees to male and female prevention,
13:04which culminated in the village of Salute,
13:07where we launched Germoglio,
13:10because our goal was to make the culture of prevention germinate
13:17and inform and educate the population.
13:22The event, which took place in Rome at the American Center for Studies,
13:25was a moment of confrontation on the future of the compartment.
13:28Together with experts from the health sector,
13:31representatives of the federal society and various pharmaceutical companies
13:34and exponents of the political world intervened.
13:37We underline the importance of scientific societies.
13:40The FISM, the Medical Scientific Society,
13:44basically brings them all together.
13:47They have an action of encouragement, support and collaboration
13:51with the national public health system.
13:53For this, we thank the professionals,
13:56Professor Tino Gesualdo,
13:58an idea of health that evidently sees in this great battle
14:04to defend the universalism of our national public health system
14:08all the players convinced and present in a battle
14:13for the defense of the fourth national public health system.
14:17The federation brings together about 200 companies with ordinary quality partners
14:21and brings together 192,000 health professionals,
14:24figures that will be increasingly central to the definition of future strategies.
14:28Today we face important challenges.
14:31The aging population, territorial inequalities, increasing chronic diseases.
14:37New formulas and new recipes must be implemented.
14:40We are committed on all fronts to the strengthening of territorial medicine,
14:46the technological innovation, the training of staff.
14:50These are all fundamental aspects on which we are working.
14:54With the FISM there is a constant, very productive and very profitable dialogue.
14:58We currently have an investigative investigation on health professions.
15:02I am sure that this common work will lead, if nothing else,
15:05to identify the right paths and then we will all strive to reach the goal.
15:10On the occasion of the meeting,
15:12the federal honorary posts were also proclaimed
15:15and the merits of public recognition were conferred to the founding members
15:19and a group of health expert journalists.
15:31Ribociclib oral therapy has obtained the approval of the EMA,
15:34the European drug regulatory body,
15:36for the treatment of the early mammary tumor HR positive, R2 negative
15:41in a large population of patients at high risk of recidivism.
15:44The approval is based on the study of phase 3 births,
15:47of which updated data have been presented at ESMO.
15:50Which have shown how ribociclib,
15:52in combination with endocrine therapy,
15:55offers a clinically significant benefit in terms of survival free of recidivism.
16:00A therapeutic indication that will allow about twice as many women
16:03with early mammary tumors,
16:05including those with lymph node-involved diseases,
16:08to benefit from it in Europe,
16:10having at their disposal a new therapeutic option
16:13in two compressed per day for three years,
16:15capable of greatly reducing the risk of recidivism.
16:18Despite endocrine therapy, in fact,
16:20more than a third of patients with an early mammary tumor diagnosis,
16:24sensitive hormone and advanced stage,
16:26could develop metastasis in other parts of the body.
16:29As underlined by Professor Michelino De Laurentiis,
16:32Director of the Complex Structure of Clinical Oncology and Experimental Dysenology
16:36of the National Institute of Young Tumors Paschal of Naples,
16:39the four-year study analysis by Nathalie
16:42has shown a further improvement of the benefit
16:44always in terms of survival free of metastasis,
16:47even after the completion of the three-year treatment period.
16:51The four-year study has shown that this therapy with ribociclib,
16:55performed with the assumption of two compressed per day for three years,
16:58in addition to standard hormone therapy,
17:01further reduces the risk,
17:03compared to all other treatments, by about 29%.
17:07This reduction appears even more marked
17:10in some populations of patients
17:12who could not previously benefit from these additional therapies,
17:16such as those without metastasis of the axillary lymph nodes,
17:19where even the reduction reaches 34%.
17:23So it is a further step forward
17:27towards our final goal,
17:29which sooner or later we will reach,
17:30which is a 0% risk of recidivism,
17:33which will obviously equate to 100% healing.
17:37For years we have believed that the hormonal-sensitive tumor
17:40was a tumor with good prognosis.
17:42In reality it is, it is not particularly aggressive.
17:45But what is the problem?
17:47That recidivisms are distributed along a very, very long time arc.
17:52Today we know that they can also occur at a distance of 20 or 30 years.
17:57And they colonize different organs,
18:00from the one at the beginning, which is the breast,
18:02and they are virtually incurable, if not in a minority of cases.
18:06So it is important to reduce recidivism
18:08to increase the definitive healing rates.
18:11A 30-year commitment in clinical research on breast cancer
18:14explains Paola Cuoco,
18:16Laffer-Sedd doctor of Novartis Italy,
18:18a pharmaceutical industry,
18:20producer of Ribociclib,
18:22which has allowed to improve the quality of life
18:24of thousands of women with breast tumors.
18:26A pathology that affects only in Italy
18:28800,000 people per 55,000 new diagnoses per year.
18:32The main goal is to try to find
18:34increasingly innovative therapeutic solutions.
18:38Novartis is committed, in the field of clinical research,
18:41with more than 240 clinical studies every year.
18:46Obviously this alone is not enough.
18:51An active collaboration is necessary
18:53with all stakeholders of the health system
18:56in order to investigate more and more
19:00the unmet needs of patients,
19:02in order to go more and more
19:06towards a personalization of the treatment
19:09and towards the possibility of ensuring
19:12that these treatments can then actually reach
19:16the patient's bed,
19:18also through partnerships
19:20with associations and institutions
19:22that allow an increasingly equal access to treatments.
19:40An advanced and effective solution
19:43to correct visual defects such as myopia,
19:46in particular in cases from moderate to severe,
19:49is what the intraocular lenses ICL represent.
19:53Thanks to a quick and safe intervention, in fact,
19:56this innovative technology is able to offer
19:59a permanent correction and a natural vision,
20:02giving patients the opportunity to live
20:05without the need for glasses or contact lenses.
20:08Contrary to what one might think,
20:10these lenses were perfect only for high values
20:14of myopia or hypermetropia.
20:16The range is around 18 diopteries for myopia
20:19and 8 diopteries for hypermetropia,
20:21also associated with astigmatic components.
20:24In fact, for many years I have adopted
20:27the implantation of this lens
20:29also for patients with medium myopia,
20:31patients who often have a clearly superior
20:34visual quality compared to any laser method.
20:37And above all, it allows me to embrace
20:40all those types of patients
20:42who cannot be operated with the laser,
20:44such as patients with eye dryness,
20:47general pathologies, very thin corns,
20:50or even pathologies such as keratoconus,
20:53perhaps in the first stage,
20:55which cannot be operated with the laser
20:57if not with particular techniques,
20:59while they can have a wonderful result
21:02through the ICL.
21:04What makes this technology distinctive
21:06is its ability to guarantee
21:08an excellent visual quality
21:10even in conditions of poor luminosity,
21:12such as night vision.
21:14Moreover, the reversibility of the intervention
21:17and the speed of recovery
21:19make it a very appreciated choice
21:21by patients with a satisfaction rate
21:23that reaches 99.4%
21:26and it is a relatively fast intervention.
21:29It is done in topical anesthesia,
21:31only with a drop supply.
21:33It needs a collaboration from the patients,
21:36so this is another very important selection criterion.
21:39Then, through a 2.75 mm micro-incision,
21:44a liquid is introduced
21:46to inflate the front chamber of the eye
21:48to create a space to put this lens,
21:51before the patient's dilation.
21:53The lens will be placed behind the iris
21:56and in front of the crystalline,
21:58so that when the iris will close,
22:00even visibly, no patient or no person
22:03will notice that the patient
22:05has something inside the eye.
22:07The intervention can last
22:09on average 5-10 minutes,
22:11but it is not a problem of speed.
22:13The important thing is to do every maneuver
22:16in the right way.
22:18Thanks to the ICL lenses,
22:20the quality of life of those suffering from myopia,
22:22like Gabriele, has significantly improved.
22:25I feel really good without glasses.
22:28For me it is a dream,
22:30after spending many years without glasses,
22:32so I am very happy to have done this intervention.
22:36I didn't even realize the timing,
22:38because it was really about 5 minutes,
22:41but it was very fast,
22:44I didn't feel any pain,
22:47it was perfect.
22:49It was a beautiful feeling,
22:51because once I struggled
22:53to get to certain characters,
22:55and now to get to 7, 8, 9, 10,
22:58for me it is a great achievement,
23:01really.
23:03I would like to thank Dr. Piotri
23:06who gave me this beautiful gift.
23:09Thank you!
23:16This was our latest news.
23:18To contact us, you can write to
23:20salutechioccioladinecronos.com
23:22Thank you for following us
23:24and see you next time.
23:33www.salutechioccioladinecronos.com